MicroRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis

Overview

Journal Curr Cancer Ther Rev

Publisher Bentham Science Publishers

Specialty Oncology

Date 2011 Sep 3

PMID 21886602

Citations 14

Authors

Larissa A Gregory

Rachel A Ricart

Shyam A Patel

Philip K Lim

Pranela Rameshwar

Affiliations

Soon will be listed here.

Abstract

The failed outcome of autologous bone marrow transplantation for breast cancer opens the field for investigations. This is particularly important because the bone marrow could be a major source of cancer cells during tertiary metastasis. This review discusses subsets of breast cancer cells, including those that enter the bone marrow at an early period of disease development, perhaps prior to clinical detection. This population of cells evades chemotherapeutic damage even at high doses. An understanding of this population might be crucial for the success of bone marrow transplants for metastatic breast cancer and for the eradication of cancer cells in bone marrow. In vivo and in vitro studies have demonstrated gap junctional intercellular communication (GJIC) between bone marrow stroma and breast cancer cells. This review discusses GJIC in cancer metastasis, facilitating roles of mesenchymal stem cells (MSCs). In addition, the review addresses potential roles for miRNAs, including those already linked to cancer biology. The literature on MSCs is growing and their links to metastasis are beginning to be significant leads for the development of new drug targets for breast cancer. In summary, this review discusses interactions among GJIC, miRNAs and MSCs as future consideration for the development of cancer therapies.

Citing Articles

Pattern of cell-to-cell transfer of microRNA by gap junction and its effect on the proliferation of glioma cells.

Peng Y, Wang X, Guo Y, Peng F, Zheng N, He B Cancer Sci. 2019; 110(6):1947-1958.

PMID: 31012516 PMC: 6549926. DOI: 10.1111/cas.14029.

MiR-216a exerts tumor-suppressing functions in renal cell carcinoma by targeting TLR4.

Wang W, Zhao E, Yu Y, Geng B, Zhang W, Li X Am J Cancer Res. 2018; 8(3):476-488.

PMID: 29637002 PMC: 5883097.

Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.

Cavaco A, Rezaei M, Niland S, Eble J Int J Mol Sci. 2017; 18(11).

PMID: 29112161 PMC: 5713324. DOI: 10.3390/ijms18112355.

Hypothesis of K-Recycling Defect Is Not a Primary Deafness Mechanism for Cx26 () Deficiency.

Zhao H Front Mol Neurosci. 2017; 10:162.

PMID: 28603488 PMC: 5445178. DOI: 10.3389/fnmol.2017.00162.

Gap junction mediated miRNA intercellular transfer and gene regulation: A novel mechanism for intercellular genetic communication.

Zong L, Zhu Y, Liang R, Zhao H Sci Rep. 2016; 6:19884.

PMID: 26814383 PMC: 4728487. DOI: 10.1038/srep19884.

References

Sasportas L, Kasmieh R, Wakimoto H, Hingtgen S, van de Water J, Mohapatra G . Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009; 106(12):4822-7. PMC: 2660771. DOI: 10.1073/pnas.0806647106. View

Mimori K, Kataoka A, Yamaguchi H, Masuda N, Kosaka Y, Ishii H . Preoperative u-PAR gene expression in bone marrow indicates the potential power of recurrence in breast cancer cases. Ann Surg Oncol. 2009; 16(7):2035-41. DOI: 10.1245/s10434-009-0465-x. View

Gakhar G, Schrempp D, Nguyen T . Regulation of gap junctional intercellular communication by TCDD in HMEC and MCF-7 breast cancer cells. Toxicol Appl Pharmacol. 2009; 235(2):171-81. DOI: 10.1016/j.taap.2008.11.020. View

Corcoran K, Trzaska K, Fernandes H, Bryan M, Taborga M, Srinivas V . Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One. 2008; 3(6):e2563. PMC: 2430536. DOI: 10.1371/journal.pone.0002563. View

Le Blanc K . Mesenchymal stromal cells: Tissue repair and immune modulation. Cytotherapy. 2006; 8(6):559-61. DOI: 10.1080/14653240601045399. View

Yang Y, Pospisil P, Iyer L, Adelstein S, Kassis A . Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS One. 2008; 3(11):e3661. PMC: 2575235. DOI: 10.1371/journal.pone.0003661. View

Potian J, Aviv H, Ponzio N, Harrison J, Rameshwar P . Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003; 171(7):3426-34. DOI: 10.4049/jimmunol.171.7.3426. View

Allgayer H, Aguirre-Ghiso J . The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?. APMIS. 2008; 116(7-8):602-14. PMC: 2821075. DOI: 10.1111/j.1600-0463.2008.00997.x. View

Etienne-Manneville S . Polarity proteins in migration and invasion. Oncogene. 2008; 27(55):6970-80. DOI: 10.1038/onc.2008.347. View

10.

Pierce B, Ballard-Barbash R, Bernstein L, Baumgartner R, Neuhouser M, Wener M . Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27(21):3437-44. PMC: 2717751. DOI: 10.1200/JCO.2008.18.9068. View

11.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

12.

Sasaki T, Takagi M, Soma T, Yoshida T . Analysis of hematopoietic microenvironment containing spatial development of stromal cells in nonwoven fabrics. J Biosci Bioeng. 2005; 96(1):76-8. View

13.

Loebinger M, Eddaoudi A, Davies D, Janes S . Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009; 69(10):4134-42. PMC: 2699841. DOI: 10.1158/0008-5472.CAN-08-4698. View

14.

Rameshwar P . Potential novel targets in breast cancer. Curr Pharm Biotechnol. 2009; 10(2):148-53. DOI: 10.2174/138920109787315024. View

15.

Hossain A, Kuo M, Saunders G . Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006; 26(21):8191-201. PMC: 1636750. DOI: 10.1128/MCB.00242-06. View

16.

Najmi S, Korah R, Chandra R, Abdellatif M, Wieder R . Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells. Clin Cancer Res. 2005; 11(5):2038-46. DOI: 10.1158/1078-0432.CCR-04-1083. View

17.

Li Z, Zhou Z, Donahue H . Alterations in Cx43 and OB-cadherin affect breast cancer cell metastatic potential. Clin Exp Metastasis. 2008; 25(3):265-72. DOI: 10.1007/s10585-007-9140-4. View

18.

Mauney J, Volloch V . Progression of human bone marrow stromal cells into both osteogenic and adipogenic lineages is differentially regulated by structural conformation of collagen I matrix via distinct signaling pathways. Matrix Biol. 2009; 28(5):239-50. PMC: 6817339. DOI: 10.1016/j.matbio.2009.04.003. View

19.

Lanzoni G, Roda G, Belluzzi A, Roda E, Bagnara G . Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol. 2008; 14(29):4616-26. PMC: 2738785. DOI: 10.3748/wjg.14.4616. View

20.

Huang G, Zhang X, Guo G, Huang K, Yang K, Shen X . Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009; 21(3):673-9. View